The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser.For the best experience on our site, be sure to turn on Javascript in your browser.
Product Rating(avorable) Unsawed Discontinued
Doxycycline 100 mg Oral Tablet Skincare Grade D & E Excellent Prescription Excellent OTC Excellent Doctor's Advice International Export Listed in Shoppers and Specialty Packages Listed on This Pack Not Defined Listed on This Pack Not Defined KNOWN
tsp-1-30 2,500 www.shoppersandESCO.com www. ESCO.com
tsp-1-40 2,500 www. ESCO.com www.uk.uk
tsp-2-30 2,500 www.uk.uk
tsp-2-40 2,500 www.teva-london.co.uk
tsp-3-30 2,500 www.teva-london.co.uk
tsp-4-30 2,500 www.teva-london.co.uk
tsp-5-30 2,500
tsp-5-40 5,000 www.teva-london.co.uk
tsp-6-30 5,000 www.teva-london.co.uk
tsp-7-30 5,000 www.teva-london.co.uk
tsp-8-30 5,000 www.teva-london.co.uk
tsp-9-30 5,000 www.teva-london.co.uk
tsp-10-30 5,000
tsp-11-30 5,000
tsp-12-30 5,000
tsp-13-30 5,000
tsp-14-30 10,000
tsp-15-30 100,000
tsp-16-30 100,000
tsp-17-30 100,000
tsp-18-30 100,000
tsp-19-30 100,000
tsp-20-30 100,000
tsp-21-30 100,000
tsp-32-30 100,000
tsp-45-30 100,000
tsp-46-30 100,000
tsp--active
tsp-act-1
tsp-act-2
tsp-act-3
tsp-act-4
tsp-act-5
tsp-act-6
tsp-1
Doxycycline 100 mg Oral Tablet is used to treat a wide variety of bacterial infections. It is used to treat only a very small number of conditions, referred to as prostatitis. Prostitis is a common condition in which a woman's prostate gland becomes enlarged which makes it hard to pass urine. Doxycycline 100 mg Oral Tablet is not recommended for use in children under the age of eight years. Take Doxycycline 100 mg Oral Tablet as prescribed and for the first time as needed, once daily. The half-life of Doxycycline 100 mg Oral Tablet is about 4 to 6 hours, therefore do not take it for more than 12 hours before lying down. Take Doxycycline 100 mg Oral Tablet with a full glass of water unless your doctor decides that you are not suitable for taking the medicine. The half-life of Doxycycline is about 24 hours, therefore do not take it for more than 24 hours before lying down.Doxycycline, also known as doxycycline hyclate is a widely used antibiotic for treating various bacterial infections, including urinary tract infections (UTIs), respiratory tract infections, and certain sexually transmitted infections (STIs). Here’s a brief overview of the drug and its uses.
The doxycycline hyclate market is projected to experience steady growth, driven by several key factors. As of 2024, the market size for doxycycline hyclate was estimated to be$ 2.7 billion, with a compound annual growth rate (CAGR) of 7.4% between January 2024 and June 3029. The increasing prevalence of infections and the need for effective treatments continue to drive the market.
The financialdisclosures analysis conducted by BNT reveals various segments and brands of doxycycline hyclate, including information on its cash grade, secondaryschools address, retail address, and online banking. These segments also present breakpoints that can help identify potential market share drivers and potential discount points.
The consumer analysis conducted by BNT is not only to highlight the market share of doxycycline hyclate, it is also to highlight the consumer preferences for its generic equivalents. The segmentation can provide insights into consumer experiences when purchasing these generic medications.
The market segmented by the type of infection, age, gender, pharmacy, and location can provide significant insights into the medications market. Healthcare providers and patients can further segment the market based on the prescribed treatment and the types of antibiotics and drugs being purchased.
The market can be segmented into tablets, capsules, and oral suspension, as these products have different uses and profiles. The tablets segment can be particularly valued for treating a wide range of bacterial infections, such as urinary tract infections (UTIs), respiratory tract infections, and certain sexually transmitted infections (STIs). The capsules segment can also be valued for treating UTIs and treating infections of the ear, nose, throat, and pharynx.
The market can be segmented into various applications and uses, including urinary tract infections, respiratory tract infections, and certain STIs. The applications segment can be particularly valued for treating UTIs and treating STIs related to middle ear, pharyngitis, sinusitis, tonsillitis, and bronchitis.
North America is expected to hold the largest share in the doxycycline hyclate market, with a market size of USD 1.2 billion in 2024. This region is expected to grow at the highest CAGR of 8.5% between January 2024 and June 2024. The region's healthcare infrastructure, coupled with its robust medical facilities and high-quality healthcare facilities, make North America the market leader in doxycycline hyclate.
The doxycycline hyclate market is dominated by Amgen, Inc., which is one of the largest manufacturers of doxycycline. Amgen is involved in several large-scale pharmaceuticals, including human and animal therapies, and is the largest of its pharmaceutical companies in North America. The Amgen-Amory brand is currently the leader in the doxycycline hyclate market, with a market size of USD 1.2 billion in 2024.
The doxycycline hyclate market is valued atUSD 1.2 billion in 2024, with a CAGR of 7.4% between January 2024 and June 3029. The cardiac and respiratory tract segment is expected to hold the largest share, with a CAGR of 8.6% from June 2024 to 2024.
Doxycycline hyclate (Doxy-HC) is used for treating bacterial infections caused by susceptible organisms, such asS. pneumoniae,orP. aeruginosa. It is a broad-spectrum antibiotic, and its activity against many organisms is limited. In clinical trials, the use of Doxy-HC has shown a significant improvement in clinical symptoms and survival rates when administered to patients. The main purpose of this study was to evaluate the efficacy of Doxy-HC in treating bacterial infections and determine the optimal dosage of Doxy-HC in patients with a history of bacterial sinusitis. Methods: Patients (aged 18–65 years) who were enrolled in the study between April and June 2009 were randomized to receive either a single dose of 10 mg/kg/day of Doxy-HC for a period of 4 weeks or a daily dose of 10 mg/kg/day of Doxy-HC for a period of 8 weeks. At the end of the trial, patients were assessed for adverse events and the efficacy of the treatment. Efficacy was measured using the percentage of symptomatic patients with a change from baseline in a standard symptom score, the patient’s improvement in the symptom score, and the improvement in a standard symptom score. Outcomes were evaluated using the Kaplan–Meier method. Statistical analyses were performed using SPSS version 20.0 (IBM, Armonk, NY). Mean differences were reported for continuous variables and frequencies and percentages for categorical variables. A p value of less than 0.05 was considered statistically significant.
A total of 19 patients were enrolled in the study. Of these, 4 patients (6 patients) met inclusion criteria. At the end of the study, 16 patients (24 patients) were included in the Doxy-HC group and 6 in the control group. The mean age was 46.2 (SD±15.1) years, with a mean age of 60.5 (SD±11.2) years in the Doxy-HC group and 65.4 (SD±18.1) years in the control group. The most common causative organisms were(n=9),(n=8),pneumoniae(n=6), andStaphylococcus aureus(n=3).
Table 1: Mean Dose of Doxy-HC in Patients with a History of bacterial sinusitis.
Table 2: Mean Dose of Doxy-HC in Patients with a History of bacterial sinusitis.
Table 3: Mean Dose of Doxy-HC in Patients with a History of bacterial sinusitis.
Table 4: Mean Dose of Doxy-HC in Patients with a History of bacterial sinusitis.
The mean (SD) difference in the mean percentage change in the symptom score (0.5 ± 0.3 vs. 1.3±0.3, P < 0.001), the mean improvement in the symptom score (0.2 ± 0.1 vs. 0.2±0.1, P < 0.001), the mean improvement in the standard symptom score (0.1 ± 0.1 vs. 0.0±0.1, P < 0.001), and the mean improvement in the standard symptom score (0.5±0.3 vs. 0.2±0.3, P < 0.001) for all patients in the Doxy-HC group and in all patients in the control group were statistically significant. The mean percentage change in the mean improvement in the standard symptom score (0.5±0.3 vs. 0.3±0.3, P < 0.001), the mean improvement in the symptom score (0.2±0.1 vs. 0.2±0.1, P < 0.001), and the mean improvement in the standard symptom score (0.1±0.1 vs. 0.0±0.1, P < 0.001) for all patients in the Doxy-HC group and in all patients in the control group were statistically significant. The mean percentage change in the mean improvement in the standard symptom score (0.1±0.1 vs. 0.0±0.
The National Institute for Clinical Excellence (NICE) guidelines on antibiotic resistance in chronic respiratory tract infections (CRUTIs) recommend that antibiotics should be used in combination with an antimicrobial stewardship (AMS) approach.
However, recent studies indicate that doxycycline (DoxyPEP) is associated with an increased risk of antibiotic resistance (AR) and has the potential to be used in combination with an AMS in the treatment of CRUTIs. To evaluate the effects of doxycycline, the National Institute for Clinical Excellence has defined the impact of AR on the treatment of CRUTIs, a subgroup of CRUTIs, and the treatment of adult patients with CRUTIs.
DoxyPEP is a prescription-only antibiotic used to treat CRUTIs. DoxyPEP is available in three strengths, 100 mg, 200 mg, and 400 mg, and is the only antibiotic that is approved for the treatment of CRUTIs. The first-line choice of antibiotic is 100 mg of doxycycline. The recommended starting dose is 200 mg for adults and 400 mg for children. Doxycycline is not recommended in the treatment of acute exacerbations of chronic bronchitis (AECB) and pneumonia, but patients can continue taking it for 4 weeks after an acute exacerbation to see if it reduces the risk of AR.
The main reason for the high prevalence of AR among patients with CRUTIs is because the CRUTI is a serious, chronic disease. The diagnosis of CRUTIs requires a specific medical history and an appropriate treatment plan, which can include antibiotics and/or corticosteroids. It is not uncommon for patients to be prescribed antibiotics as a first-line option, with a recommendation to take this first-line treatment at least 2 weeks before an AECB or respiratory infection. Patients who develop AR are at risk of developing resistance, and a first-line antibiotic should be given for 6 weeks after the CRUTI diagnosis.
A study of antibiotic use in children with CRUTIs found that DoxyPEP is associated with an increased risk of AR, as judged by the NICE guideline. In that study, the patients were enrolled in a multicentre, randomized, double-blind, placebo-controlled, fixed-dose study of DoxyPEP, a long-acting, single-dose formulation of doxycycline (400 mg twice daily) and a second-generation, extended-release, doxycycline tablet (200 mg once daily) for 12 weeks. These two formulations of doxycycline are associated with the most common AR, but it is not known whether these findings are related to the first-line formulation. The investigators noted that they did not have a routine review of DoxyPEP, and therefore do not recommend its use in children, but it is recommended in adults to be considered for the treatment of CRUTIs and AECB, as the first-line treatment. In adults, the risk of AR has been identified from the NICE guidelines. However, the study has not been designed to assess the risk of AR in patients with CRUTIs.
In the past, the risk of AR was assessed using the Streptococcus pneumoniae agalactia test (SPAT) test. In the present study, the investigators found no association between the number of spirochetes and AR. However, the study did not report any information about the use of doxycycline in patients with CRUTIs.
The study authors note that the NICE guideline does not specifically recommend the use of doxycycline in the treatment of patients with CRUTIs. The NICE guidelines do not recommend the use of DoxyPEP in the treatment of CRUTIs, and doxycycline is not approved by the NICE guidelines for the treatment of CRUTIs. In the present study, the investigators found no association between doxycycline use and AR.
Stade de France Pharmacy